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Introduction
In this era of precision medicine, targets for new drugs are
to be found across the range of tumors. Tissue microar-
rays are often used for that purpose, and for instance,
Fernandez et al. [1] stained 395 lymphomas for Bruton’s
tyrosine kinase protein expression showing that many B
cell lymphomas, some T cell lymphomas, 14/16 nodular
lymphocyte predominant, and 6/27 classic Hodgkin lym-
phoma (cHL) were positive. However, expression of a
protein does not fully correlate with therapy response, so
such studies can only serve as an initial screen. A next
step is to study the effect of a drug in cell lines, like the
work of Choudhary et al. [2], who investigated the effect
of a Bcl-2 inhibitor on B cell lymphoma cell lines and
also the acquired resistance after treatment. They showed
that the B cell lymphoma cells upon treatment with Bcl-2
inhibition increased their expression of MCL-1 and Bcl-x,
which resulted in resistance that could be overcome by
inhibition of these factors. The authors indicate that a
combination of these drugs might be a good rationale
for therapy. However, I would be concerned when treat-
ments would be based on physiological rather than path-
ological changes in neoplastic cells. In other words, such
studies in follicular lymphoma seem to be more important
than in lymphomas without BCL2 alterations, even though
the expression of the protein might be the same. Of




Neoplastic cells have many dysregulated transcription path-
ways. By looking at the accessible sites of the chromatin in
specific lymphoma types, Kreher et al. [3] discovered that in-
terferon regulator factor (IRF) in cHLwas a candidate for being
specifically important for lymphoma development. In cell lines,
they found that IRF5 is highly expressed and crucial for sur-
vival; they suggest that this factor has therefore a key tumor
promoting role. cHL is characterized by the interplay between
neoplastic cells and the microenvironment, and the amount of
macrophages is an indicator for prognosis. Tudor et al. [4]
analyzed 106 specimens using immunohistochemistry and
found that high numbers of CD83 positive dendritic cells and
low numbers of CD163 positive macrophages indicate im-
proved survival. Furthermore, they found by RT-PCR in many
samples increased levels of cytokines, both pro- and anti-in-
flammatory. Based on their data and cell-experiments, they
propose a model by which cHL-cells induce maturation of
dendritic cells, and vice versa, that macrophages promote im-
mune evasion of cHL-cells.
B cell lymphomas
Bauman et al. [5] searched in mantle cell lymphoma (MCL)
for genetic alterations and found a common small deletion in
FBXO25 and monoallelic loss, resulting in lack of apoptosis
through the mitochondrial protein HAX-1. The authors there-
fore conclude that FBO25 is a tumor suppressor in MCL and
HAX-1 a protooncogene.
Tumor heterogeneity is a hot topic in cancer research.
Spence et al. [6] used an original approach to study this
phenomenon in follicular lymphoma (FL). They
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reasoned that activation-induced deaminase (AID) not
only results in physiological somatic hypermutation
(SHM) in the immunoglobulin genes (Ig), but also in
o the r genes , r e f e r r ed to as aber r an t soma t i c
hypermutation (aSHM). Using ultradeep sequencing,
they found single nucleotide variants in 12/12 FL with
a median of 136 SHM and 53 aSHM. The number of
variants at the BCL2 locus correlated with other non-Ig
loci, but not with Ig heavy chain gene (IgH). They
conclude that genome-wide aSHM can be deduced by
looking at the BCL2 locus only.
Because they previously showed that about 40 % of
extranodal marginal zone lymphoma (ENMZL) of the salivary
gland express high affinity stereotypic rheumatoid factor B
cell receptors, Bende et al. [7] investigated whether this is also
the case in salivary gland biopsies of patients with Sjogren’s
syndrome; they found this to be the case in 2/4 of such biop-
sies, but most of the clones they found had other B cell recep-
tors. One of these two patients developed a diffuse large B cell
lymphoma (DLBL) from the clone that expressed the rheuma-
toid factor recognizing receptor indicating a selection advan-
tage of these receptors predisposing for lymphoma
development.
Not only autoimmune disease predisposes for lym-
phoma development, but also hepatitis C infection.
Arcaini et al. [8] investigated the relation between
NOTCH-pathway mutations and hepatitis C-related lym-
phomas and found NOTCH2 mutations in 9/46 (20 %)
hepatitis C virus-positive DLBL patients, and NOTCH1
mutations in 2/46 (4 %). By contrast, only 1/64 HCV-
negative patient had a NOTCH1 or NOTCH2 mutation.
The 5-year overall survival was 27 % for patients with
a NOTCH pathway mutated DLBL versus 62 % for
those without. Notch 2 is a critical membrane receptor
for B cell functions and also displays various biological
roles in lymphoma pathogenesis. Zhang et al. [9] show
that a truncate NOTCH2 mutation activates both the
Notch 2 and the NF-κB signals and promotes the pro-
liferation of B cell lymphoma cell lines. This prolifera-
tion was completely inhibited by ammonium pyrrolidine
dithiocarbamate (PDTC), an NF-κB inhibitor. Simulta-
neously, PDTC also reduced the expression level of
Notch 2 so that this may become a new therapeutical
approach.
NOTCH inducesMYC, connecting two signaling programs
that are involved in lymphomagenesis. Ortega et al. [10] show
that this relationship is bidirectional and that MYC, via a
miRNA intermediary, modulates NOTCH. MicroRNA-30a
(miR-30a), a member of a family of miRNAs that are tran-
scriptionally suppressed by MYC, directly binds to and in-
hibits NOTCH1 and NOTCH2 expression. The activity of
the miR-30a—NOTCH—MYC loop was validated in primary
DLBL and T-ALL samples.
Another prime interest in B cell lymphomas is the
NF-κB pathway, for which there are potential inhibitors
for treatment. This pathway is activated in different
lymphoma types through activating mutations. A sub-
type of DLBL with such mutations is primary central
nervous system (CNS) DLBL, which has an aggressive
clinical behavior. It has been seen as an immune
privileged site due to the blood-brain barrier, and the
question is how B cell receptor (BCR) activation is
taking place. Akhter et al. [11] have analyzed the ex-
pression of 19 genes of the Toll-like receptor (TLR)/
BCR pathway and targets in 20 cases of CNS DLBL.
Compared to systemic DLBL, there was higher expres-
sion of TLR9, CD79B, CARD11, LYN, and BLNK.
The B cell receptor molecules like BLNK and CD79B
were also associated with higher expression of MYD88-
dependent TLRs (TLR4/5/9). TLR overexpression is
closely related with up-regulation of genes associated
with BCR pathway like CD79B/BLNK and CARD11,
which play an important role in NF-kB pathway activa-
tion. These results provide an important insight into the
possibility of TLR and/or B cell receptor signaling mol-
ecules as possible therapeutic targets in CNS DLBL.
According to Gebauer et al. [12], primary mediastinal
large B cell lymphoma has no mutations in CARD11,
CD79B, or EZH2, based on 25 cases, but nevertheless
may benefit from NF-κB inhibition since this pathway
is also activated through B cell receptor signaling.
Using this argument, any B cell lymphoma may benefit.
Actually, these studies indicate that there is a need for a
good marker for NF-κB activation.
T cell lymphoma
Increasingly new targets for therapy are being discovered in B
cell lymphomas, but fewer in T cell lymphomas although the-
se have generally a poorer prognosis. Martin-Sanchez et al.
[13] investigated the potential therapeutic value in T cell lym-
phomas of the Proviral Integration site of Moloney murine
leukemia virus (PIM) kinases, which are overexpressed in
peripheral T cell lymphomas (PTCL) and important mediators
of cell survival. Inhibition of individual PIM kinases in a panel
of 8 PTCL cell lines did not affect survival, partially because
of a compensatory mechanism among the three PIM genes. In
contrast, pharmacological inhibition of all PIM kinases
strongly induced apoptosis in all PTCL cell lines, without cell
cycle arrest, in part through the induction of DNA damage.
Therefore, pan-PIM inhibitor (pan-PIMi) synergized with cis-
platin. Importantly, pharmacological inhibition of PIM re-
duced primary tumoral T cell viability without affecting nor-
mal T cells ex vivo. Since anaplastic large cell lymphoma
(ALK+ ALCL) cell lines were the most sensitive to the pan-
PIMi, they tested the simultaneous inhibition of ALK and PIM
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kinases and found a strong synergistic effect in ALK+ ALCL
cell lines. These findings suggest that PIM kinase inhibition
could be of therapeutic value in a subset of PTCL.
Anaplastic large cell lymphoma (ALCL) is one of the most
common T cell non-Hodgkin lymphomas and has two main
subtypes: an anaplastic lymphoma kinase (ALK)-positive
subtype characterized by ALK gene rearrangements and an
ALK-negative subtype that is poorly understood. Xing et al.
[14] recently identified recurrent rearrangements of the
DUSP22 locus on 6p25.3 in both primary cutaneous and sys-
temic ALK-negative ALCLs. Since CCR8 has skin-homing
properties it has been suggested to play a role in limiting
extracutaneous spread of primary cutaneous ALCLs although
overexpression of CCR8 has also been reported in systemic
ALK-negative ALCLs. Using quantitative real-time PCR in
frozen tissue and RNA in situ hybridization (ISH) in paraffin
tissue showed higher CCR8 expression in ALCLs with
DUSP22 rearrangements than in nonrearranged cases. CCR8
expression was not associated with cutaneous presentation,
cutaneous biopsy site, or cutaneous involvement during the
disease course. These findings suggest that CCR8 expression
in ALCL is more closely related to the presence of DUSP22
rearrangements than to cutaneous involvement and that the
function of CCR8 may extend beyond its skin-homing prop-
erties in this disease.
Weilemann et al. [15] investigated ALCL as well as focus-
ing on the interferon regulatory factor 4 (IRF4), known to be
highly expressed in both ALK-positive and ALK-negative
cases. They show that ALCLs of both subtypes are addicted
to IRF4 signaling, as knockdown of IRF4 by RNA interfer-
ence was toxic to ALCL cell lines in vitro and in ALCL
xenograft mouse models in vivo. Gene expression profiling
after IRF4 knockdown demonstrated a significant downregu-
lation of a variety of known MYC target genes. Furthermore,
our analyses revealed that MYC is a primary target of IRF4,
identifying a novel regulatory mechanism ofMYC expression
and its target gene network in ALCL.MYC, itself, is essential
for ALCL survival, as both knockdown ofMYC and pharma-
cologic inhibition of MYC signaling were toxic to ALCL cell
lines. Collectively, these results demonstrate that ALCLs are
dependent on IRF4 and MYC signaling and that MYC may
represent a promising target for future therapies.
Epidemiology of lymphoma
Although lymphomas are rarely seen in hereditary cancer syn-
dromes, familial clustering suggests that there are susceptibil-
ity loci that enhance the risk to develop a lymphoma. Since
lymphoma types are separate entities, association studies need
to focus on well-defined entities such as FL, for which already
such loci (HLA-variants) have been described. Skibola et al.
[16] in a huge team effort, combined data from many patients
and controls: 4523 case subjects and 13,344 control subjects
of European ancestry. Five non-HLA loci were associated
with FL risk: 11q23.3 near CXCR5; 11q24.3 near ETS1;
3q28 in LPP; 18q21.33 near BCL2; and 8q24.21 near PVT1.
These findings further expand the number of loci associated
with FL and provide evidence that multiple common variants
outside the HLA region make a significant contribution to FL
risk. Nevertheless, the increased risk is not substantial and not
sufficient to use these data in screening or risk assessment.
Cerhan et al. [17] performed a meta-analysis of similar studies
in DLBL, which is a much less defined entity, totaling 3857
cases and 7666 controls of European ancestry. Five indepen-
dent SNPs in four loci achieved genome-wide significance at
6p25.3 (EXOC2), 6p21.33 (HLA-B), 2p23.3 (NCOA1), and
two independent SNPs at 8q24.21 (PVT1). Although the au-
thors indicate that these data provide substantial new evidence
for genetic susceptibility to this B cell malignancy and point to
pathways involved in immune recognition and immune func-
tion in the pathogenesis of DLBL, it is indeed problematic that
this analysis uses DLBL as one group. It is therefore hard to
see how these data bring us further in understanding
lymphomagenesis.
More interesting is the work of Muwazi et al. [18] although
it is published in a much less prestigious journal (see editorial
in this issue). They analyzed the seasonal variation in inci-
dence of Burkitt lymphoma (BL), a well-defined entity with
clear environmental aspects. All cases diagnosed from 1969 to
2006, from all over Uganda, at the Makerere University’s
Department of Pathology, were evaluated with respect to
monthly and rainy versus dry season prevalence. Although
monthly frequencies varied considerably over the period, the-
se differences were not significant; likewise, there was no
statistically significant difference in the total number of
Burkitt’s during the rainy compared dry seasons. These results
indicate that mosquitoes are probable not directly involved in
the pathogenesis.
Reference data from many patients in rare diseases can
only be gathered by collaborative efforts. Munch-Petersen
et al. [19] collected data from six eye cancer centers, over a
period of 30 years, on 100 patients with ocular adnexal (OA)-
DLBL. Themedian age was 70 years and 54 were female. The
following three groups of patients with lymphoma could be
identified: primary OA-DLBL (57.0 %), OA-DLBL and con-
current systemic lymphoma (29.0%), and ocular adnexal lym-
phoma relapse of previous systemic lymphoma (14.0 %). Of
57 patients with primary OA-DLBL, 53 (93.0 %) had Ann
Arbor stage IE disease, and 4 (7.0 %) had Ann Arbor stage
IIE disease. According to the TNM staging system, 43 of 57
(75.4 %) had T2 tumors. Among all patients, the most fre-
quent treatments were external beam radiation therapy with
or without surgery (31.0 %) and rituximab-cyclophospha-
mide, hydroxydaunorubicin, vincristine sulfate, prednisone
(CHOP), or rituximab-CHOP-like chemotherapy with or
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without external beam radiation therapy (21.0 %). The 5-year
overall survival among the entire cohort was 36.0 %. Relapse
occurred in 43.9 % (25 of 57) of patients with primary OA-
DLBL. Increasing T category of the TNM staging system was
predictive of survival in primary OA-DLBL, whereas the Ann
Arbor staging system was not.
Defining entities
B cell lymphomas
As described above, patients with Sjogren syndrome have an
increased risk on lymphoma but also have expanded B cell
clones in the inflammatory phase of the disease. Johnsen et al.
[20] analyzed biopsies from 21 Sjogren syndrome patients
with lymphoma. GC-like structures (a term I actually do not
like: germinal centers are very well defined, and it seems that
primary follicles are included by the authors) in 17/40 (43 %)
of the patients: 4/12 (33 %) with and 13/28 (46 %) without
lymphoma. Surprisingly, monoclonal B cell infiltration was
present in 5/12 patients (42 %) with and 5/28 patients
(18 %) without lymphoma, which is in sharp contrast with
other studies, in which virtually all lymphomas show
clonality.
Gebauer et al. [21] collected 30 NMZL en performed
microRNA profiling on low grade cases and cases that trans-
formed to DLBL. While microRNA signatures of low-grade
and transformed NMZL did not differ significantly, several
microRNAs were differentially expressed between trans-
formed NMZL and de novo DLBL. These are potentially
relevant findings, because separating de novo DLBL from
transformed cases may be clinically relevant.
Low grade B cell lymphomas primarily arising in the
spleen are often difficult to classify, partly because they are
rare, partly because there are overlapping features of the enti-
ties. Piva et al. [22] found recurrent mutations of the Kruppel-
like factor 2 (KLF2) gene in 19/96 cases of splenic marginal
zone lymphoma (SMZL); mutations were also found in other
lymphoma types, but generally in lower frequencies: 16 %
(4/24) of hairy cell leukemia (HCL), 11 % (17/154) of DLBL,
9 % (5/56) of NMZL, and 8 % (5/61) of extranodal marginal
zone lymphomas (EMZL). They were rare or absent (frequen-
cy=0–4 %) in the remaining lymphoma entities. Clipson et al.
[23] investigated the same gene in the same number (coinci-
dentally also 96!) of cases of SMZL but found more than
twice as many mutations: 40, and rarely in other B cell lym-
phomas. In this study, IGHV1-2 rearrangement and 7q dele-
tion were primarily seen in SMZL with KLF2mutation, while
MYD88 and TP53mutations were nearly exclusively found in
those without KLF2 mutation. NOTCH2, TRAF3, TNFAIP3,
and CARD11 mutations were observed in SMZL both with
and without KLF2 mutation. Both studies indicate that KLF2
mutation is the most common genetic change in SMZL, but
sensitivity and specificity and the relation to other genetic
alterations remains to be studied further.
Primary site of presentation is determining an entity for
some specific lymphomas, like the skin, the mediastinum, or
the testis. Primary presentation in the ovary is rare, and it is not
clear that it represents a real subgroup. Sun et al. [24] studied
14 cases of which 12 were DLBL and 2 BL. The DLBL were
all of the germinal center type and one had a MYC and BCL2
break. The treatments and outcomes were highly variable, and
it seems there are few arguments to categorize these as a sep-
arate entity.
Satou et al. [25] compared 33 EBV-positive BL with 117
EBV-negative cases from Japan. EBV-positive cases present-
ed in older patients, more often in the tonsil and lymph nodes,
whereas EBV-negative cases were more often located in the
digestive tract. Based on these findings, the authors suggest
that EBV-positive BL is an age-related disease. I am not sure
that this concept really will be as successful as the EBV-
positive DLBL of the elderly.
T cell neoplasia
The diagnosis of T-lymphoblastic lymphoma/leukemia (T-
LBL) can be a pitfall when it presents in the thymic regions:
like thymocytes, the cells express TdT and Mib1 is almost
100 %. Of course, clonality testing can be helpful but takes
time and is not everywhere available. Since the NOTCH path-
way is frequently activated in T-LBL, Jegalian et al. [26] in-
vestigated whether an antibody to the NOTCH1 intracellular
domain (N1ICD), which recognizes activated NOTCH1,
might be a helpful diagnostic tool. Hyperplastic tonsil showed
positivity in few scattered interfollicular lymphoid cells,
suprabasilar epithelial cells, and endothelial cells. Thymocytes
from non-neoplastic thymus were largely negative for N1ICD.
All thymomas tested (n=23) were negative for N1ICD, al-
though epithelial cells and a small minority of thymocytes
may be positive, requiring careful interpretation. All T-LBL
cases (n=16) were scored positive for N1ICD: 8 (50 %) of
these showed diffuse and mostly strong immunoreactivity,
whereas the remaining 8 (50 %) had less extensive positivity,
but with consistently >25 % nuclear staining. Thus, N1ICD
immunohistochemistry appears to be a useful method in
distinguishing T-LBL from thymoma.
Also in T cell lymphomas, microRNAs were studied.
Laginestra et al. [27] generated a microRNA profile of 23
peripheral T cell lymphomas (PTCL). The microRNA signa-
ture was compared with the gene expression profile of the
same neoplasms. Two sets of microRNAs were identified that
distinguished PTCL from angioimmunoblastic T cell lympho-
ma (AITL) and anaplastic large-cell lymphomas (ALCL)
ALK-negative, respectively. This however seems to me a
complicated way to reach a diagnosis.
24 J Hematopathol (2015) 8:21–29
Ng et al. [28] performed gene expression profiling in EBV-
associated T/natural killer (NK)-cell lymphoproliferative dis-
order in children and young adults (TNKLPDC) in order to
understand the molecular pathways deregulated in this disease
and compared the results with those obtained in nasal-type
NK/Tcell lymphoma (NKTL). The molecular and phenotypic
signature of TNKLPDC is similar to NKTL, with overexpres-
sion of p53, survivin, and EZH2. Down-regulation ofEZH2 in
TNKLPDC cell lines led to an increase in apoptosis and de-
crease in tumor viability, suggesting that EZH2may be impor-
tant for the survival of TNKLPDC cells and hence potentially
a useful therapeutic target. Gene expression profiling revealed
a distinctive enrichment of stem cell-related genes in TNKL
PDC compared to NKTL. This was validated by a significant-
ly higher expression of aldehyde dehydrogenase 1 (ALDH1)
in TNKLPDC cell lines compared to NKTL cell lines.
Nakamoto-Matsubara et al. [29] looked for a better diag-
nostic tool to identify angioimmunoblastic T cell lymphoma
(AITL) and separate it from PTCL using whole-exome and
subsequent targeted sequencing. They identified G17VRHOA
mutations in 60–70 % of AITL and AITL-like PTCL-NOS
cases but not in other hematologic cancers, including other T
cell malignancies. If confirmed, this could serve as a novel
marker for AITL and AITL-like PTCL. It obviously raises the
questions whether the latter are really not AITL.
Cutaneous lymphomas
The spectrum of cutaneous CD30-positive lymphoprolifera-
tive disorders (LPDs) includes lymphomatoid papulosis and
primary cutaneous anaplastic large cell lymphoma. Using
whole-transcriptome sequencing, Velusamy et al. [30] identi-
fied a chimeric fusion involving NPM1 (5q35) and TYK2
(19p13) that encodes a NPM1-TYK2 protein containing the
oligomerization domain of NPM1 and an intact catalytic do-
main in TYK2. Fluorescence in situ hybridization revealed
NPM1-TYK2 fusions in 2 of 47 (4 %) primary cases of
CD30-positive LPDs and was absent in other mature T cell
neoplasms (n=151). This is the first report of recurrent trans-
locations involving TYK2.
Another difficult diagnosis in skin biopsies is early mycosis
fungoides (MF). Ralfkiaer at al. [31] used a global quantitative
real-time polymerase chain reaction platform to study
microRNA expression in patients with earlyMF (n=13), more
advanced cutaneous (C)TCL (n=42), and atopic dermatitis
(AD, n=20). Thirty-eight microRNAs were differentially
expressed (≥twofold) in early MF vs. AD and 36 in early
MF vs. more advanced disease. In early MF, additional miRs
were significantly up-regulated compared to more advanced
CTCL. In the 16 patients for whom detailed follow-up data
were available, 72 miRs were found differentially expressed
between patients with progressive vs. those with non-
progressive disease. These data suggest that miR profiling in
CTCL may be a key to improving both diagnosis and risk
prediction, but this method that is not commonly available
would need extensive validation.
Oschlies et al. [32] who have a rich pediatric lymphoma
case collection describe their pediatric subcutaneous
panniculitis like Tcell lymphoma (SPLTCL), which is defined
as α/β T cell receptor positive T cell lymphoma of CD8 pos-
itive cytotoxic T cells involving exclusively the subcutaneous
tissue. SPLTCL is rare but has been shown to affect all age
groups including children. The clinical course of this lympho-
ma depends on the presence or absence of a hemophagocytic
syndrome (HPS), which has been reported to develop second-
arily in approximately 20 % of SPLTCLs usually associated
with an unfavorable outcome.
Pitfalls in lymphoma diagnosis
Kaneko et al. [33] attempted to clarify the clinicopathological
and immunohistochemical findings and presence or absence
of Epstein-Barr virus (EBV) in tonsillar atypical interfollicular
hyperplasia (AIFH). A total of 597 consecutive specimens
from tonsillectomies performed between 1999 and July 2013
were reexamined. AIFH was identified in the tonsils in 12
(2.0 %) cases. These included seven males and five females,
aged 3 to 19 years. Histologically, there was an expansion of
the interfollicular areas by polymorphous infiltration resulting
in distortion, but not obliteration of the normal tonsillar archi-
tecture. In some areas, the lymphoid follicles had hyperplastic
germinal centers with ill-defined borders surrounded by sheet-
like proliferation of polymorphous infiltrate showing a mar-
ginal zone distribution pattern. The infiltrate was composed of
small to medium-sized (transformed) lymphocytes and
immunoblasts accompanied by numerous plasma cells and
plasmacytoid cells and resembling monocytoid B cells. The
numerous immunoblasts were MUM1(+), CD10(−), BCL-
6(−). EBER was positive in 9 of the 12 lesions. Although
EBV-infection in tonsils is indeed a real pitfall, I do not think
it is helpful to coin the term AIFH, which to me suggest a
problem (atypical is often used in the setting of cancer) that is
not real. Recognizing that transformed cells and distortion of
the architecture can occur in reactive EBV lesions is more
important that suggesting a new name for the lesion.
Prognostic factors in lymphoma
Barreca et al. [34] used a novel single molecule RNA fluores-
cence based in situ hybridization to quantify BCL2 RNA ex-
pression in FL cells. They discovered a highly variable ex-
pression in cells of a single lymphoma, and there was a cor-
relation with the level of Ig RNA expression. The results are
somewhat surprising since the protein levels are not very
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variable between the cells within a lymphoma. Having no
experience with this specific technique, but with other RNA-
based technologies, I wonder whether technical issues might
be an issue. I am not sure that this is going to be a potential
prognostic marker. There is more potential in the discovery of
Correia et al. [35] who found that in FL, there is not only a
translocation involving BCL2 but there may also be mutations
in the BCL2 gene. The prevalence of BCL2 coding sequence
mutations was 12 % in FL at diagnosis and 53 % at transfor-
mation. The presence of these BCL2 mutations at diagnosis
correlated with increased risk of transformation and largely
increased risk of death due to lymphoma.
The recognition of the importance of the immune response
in cancer development has led to many articles on the prog-
nostic impact of inflammatory cells in a variety of tumors.
Nygren et al. [36] used flow cytometry in diagnostic MCL
(n=153) biopsies. MCL cases with diffuse and nodular histo-
logic subtypes showed lower levels of T cells, especially CD4
Tcells, than those with mantle zone growth pattern. Both CD3
and CD4 cells were lower in the nodular subtype than in
mantle zone and in the diffuse compared with the nodular
subtype. The CD4:CD8 ratios were inversely correlated to
tumor cell proliferation. Higher levels of CD3 and CD4 Tcells
and higher CD4:CD8 ratios were associated with indolent
disease. In multivariate analysis, the CD4:CD8 ratio correlat-
ed with overall survival independently of MCL-International
Prognostic Index and high p53 expression.
Vajpayee et al. [37] correlated immunohistochemical ex-
pression of mTORwith germinal center and nongerminal cen-
ter phenotype, BCL2 and MYC expression, and International
Prognostic Index (IPI) score in 31 patients with DLBL. Virtu-
ally, all patients with high mTOR scores had a germinal center
phenotype, and within the germinal center subgroup, patients
with high mTOR scores had higher IPI scores. Obviously,
these data point to a potential indication of mTOR inhibitors
for these patients.
Several studies have been performed using MYC immuno-
histochemistry to either define a lymphoma subgroup or as a
prognostic indicator. Huang et al. [38] looked for MYC-ex-
pression in 69 ENMZL, including 42 cases without transfor-
mation, 20 cases with transformation and 7 cases of DLBCL
with an ENMZL component. In total, 15/42 (35.7 %) cases
were nuclear positive for MYC expression in the group with-
out transformation, whereas 15/20 (75.0 %) cases were posi-
tive in the group with transformation and 4/7 (57.1 %) in the
group of DLBCL + ENMZL. Therefore,MYC overexpression
may play an important role in aggressive transformation, but
the finding is surprising and needs confirmation.
Mahmoud et al. [39] took up the important challenge to
validate MYC expression as a prognostic marker by looking
at the reliability of its scoring by hematopathologists. Immu-
nohistochemical evaluation of MYC protein expression in
DLBL is a potential prognostic tool. Concordance of scoring
in these studies was assessed among few pathologists from
one institution by scoring tissue microarrays. In daily practice,
MYC evaluation is performed on entire tumor sections by a
diverse group of pathologists. Nine hematopathologists from
two institutions scored whole-tissue sections of two sets of
cases: a training set of 13 cases of DLBL and 4 cases of
Burkitt lymphoma (BL) and a validation set of 18 cases of
DLBL and 1 case of Burkitt lymphoma. MYC positivity was
defined as ≥40 % of tumor cells demonstrating nuclear stain-
ing similar to prior studies. Discrepant cases from the training
set were characterized by staining heterogeneity, extensive
necrosis, or crush artifact and had mean scores within 15 per-
centage points of 40 %. Cases from the validation set that
demonstrated any of these features were scored twice on two
different days. Overall concordance was moderate (Kappa
score, 0.68; P value<0.001) with no significant change be-
tween the two sets (Kappa scores, 0.69 vs 0.67). Thirty-nine
percent of cases were discrepant. The findings indicate that a
significant number of diffuse large B cell lymphomas are in-
herently difficult to score due to staining heterogeneity. Care-
ful scoring strategy in their study failed to improve concor-
dance. This result is worrisome, but likely realistic: it shows
that quantification by pathologists is inherently difficult and
probably should be left to computerized approaches.
Coutinho et al. [40] took up the challenge to translate a
gene expression profile into a prognostic tool based on immu-
nohistochemistry. One has to realize that this is not yet very
well possible for the identification of activated and germinal
center types of DLBL. Diagnostic tissue from 309 patients
was arrayed onto tissue microarrays. Results from 161
chemoimmunotherapy-treated patients were used for outcome
prediction. By using computerized image analysis, they avoid
the subjective interpretation by pathologists: positive cells,
percentage stained area, and numbers of pixels/area were
quantified. The concordance between two systems of image
analysis was surprisingly high, supporting their applicability
for immunohistochemistry studies. Patients with high density
of CD3 positive cells and FoxP3 positive cells by both
methods had a better outcome.
Chan et al. [41] profiled 148 genomes with 91 matching
transcriptomes in a R-CHOP-treated DLBL cohort to uncover
molecular subgroups linked to treatment failure. They found
that deletions in RCOR1 were associated with unfavorable
progression-free survival. They compiled a gene signature that
identified a subgroup of patients with unfavorable overall sur-
vival. The prognostic significance of this 233-gene signature
was reproduced in an independent cohort comprising 195 R-
CHOP-treated patients. Additionally, within the IPI low risk
group, the gene signature provided additional prognostic val-
ue that was independent of the cell-of-origin phenotype. This
may therefore be a novel molecular subgroup of DLBL, al-
though it remains unclear why simple detection of RCOR1
deletions are not the way to go.
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Staging
It has been shown already many times that the amount of
neoplastic cells in the bone marrow of FL patients indicate
prognosis and that even low levels of these cells are
prognostically relevant. Berget et al. [42] compared clonality
testing, histology, and flow cytometry for detection of bone
marrow involvement in FL patients. Indeed, patients with mo-
lecular but without morphological involvement had a poorer
outcome. Surprisingly, patients with morphological and/or
flow cytometrical involvement had the same outcome as pa-
tients without: this finding is so at odds with existing data that
one must doubt the findings.
Ancillary techniques
Challagundla et al. [43] measured CD200 expression levels in
505 peripheral blood, bone marrow, and lymphoid tissue bi-
opsy specimens, including 364 cases positive for B cell leu-
kemias and lymphomas. CD200 expression in chronic lym-
phocytic leukemia cases was as bright as or brighter than
normal B cells in nearly all cases, while MCL cases were
usually dim or negative. However, rare MCL cases (about
5 %) were moderately bright for CD200. MZL varied by sub-
type, with nodal cases brighter, splenic cases dimmer, and
extranodal cases heterogeneous for CD200 expression. FL
cells were brighter for CD200 in bone marrow specimens than
in lymph nodes. DLBL of the non-germinal center type tended
to be brighter for CD200 than those of the germinal center
type, while BL were negative. They conclude that CD200
staining by flow cytometry can be useful in the differential
diagnosis of B cell neoplasms and in their detection in the
bone marrow, although the additional value to the standard
approach was not given in this study.
Light chain restriction can be a helpful tool in defining B
cell proliferations, but is not always easy to determine due to
technical issues. Minca et al. [44] used ultrasensitive bright-
field mRNA-ISH (BRISH) for in situ light-chain detection in
cutaneous B cell lymphomas on 27 skin biopsies and exci-
sions from patients with available results of B cell PCR-based
clonality studies: 16 clonal B cell lesions and 11 non-clonal B
cell proliferations. BRISH was successful in 15/16 clonal B
cell lesions and 11/11 non-clonal proliferations. Light-chain
restriction was detected in 15/15 clonal lesions and in 1/11
non-clonal proliferations (96.1 % overall concordance with
clonality PCR). Therefore, ultrasensitive BRISH can success-
fully detect light-chain restriction in B-NHL from skin speci-
mens and may be a useful adjunct ancillary tool.
Interpretation of the results of a clonality test is not always
straightforward. Park et al. [45] used the Euroclonality/
BIOMED2 primer set in 274 consecutive samples. Partly
based on the guideline of Euroclonality (Langerak et al.
[46]), they reported the results of 274 consecutive clonality
cases and determined the interobserver reproducibility of in-
dividual primer set reactions and final results in a subset of 30
cases; 44/161 (27 %) B cell and 50/163 (31 %) T cell cases
contained at least one abnormal peak. Of these, 29 (64 %) and
31 (62%), respectively, showed clonal results in another prim-
er set. Interobserver reproducibility was excellent for most
primer sets and for final interpretations, but only fair to good
for IGK V-J and TCRB D-J1+2 primer sets. A definitive
diagnosis of lymphoma was rendered in 93, 20, and 6 % of
B cell cases and 90, 42, and 14 % of T cell cases positive,
indeterminate, or negative for a clonal population, respective-
ly. The authors conclude that although abnormal (equivocal)
peaks are frequently observed in routine practice, most of
these contain clonal rearrangements in other primer sets, fa-
cilitating overall interpretation of final results with excellent
interobserver reproducibility. This is in line with the experi-
ence that complementarity of the primer sets is a very impor-
tant element in the Euroclonality approach. This is especially
relevant when dealing with formalin-fixed, paraffin-
embedded tissue. Moharrami et al. [47] also used the
BIOMED-2 protocols to determine the clonality of IGH gene
rearrangements in patients with lymphoma. PCR amplifica-
tion was performed on FFPE of 50 patients with B cell lym-
phoma, which consisted of 11 cases with cHL, 25 cases of B-
NHLs, and 14 cases of unclassifiable B-NHL. There was a
clonal result in 96 % (24/25) of B-NHLs, whereas in cHL
82 % (9/11) of cases were clonal. These rates of clonality
was not reached for a single target (FR1, FR2, FR3), which
also confirms the importance of a complete approach.
Open Access This article is distributed under the terms of the Creative
Commons Attribution License which permits any use, distribution, and
reproduction in any medium, provided the original author(s) and the
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